The clinical applications of discoveries in angiogenesis and vasculogenesis research necessitate the development and validation of surrogate markers of tumour neovascularization and anti-angiogenic drug efficacy. Candidate biomarkers include circulating endothelial cells (CECs) shed by the tumour vasculature and circulating endothelial progenitors (CEPs) derived from the bone marrow, both measured by multiparametric flow cytometry. In their remarkable Review . Nevertheless, the lack of haematopoietic antigen expression, such as CD45, has also been used to show the endothelial nature of CEPs and CECs 6, 7 . In addition, studies in murine models have documented the existence of bone-marrow-derived SCA1 . These differences might reflect, in part, our limited understanding of the potential origin and steps of differentiation of CEPs toward the endothelial lineage in postnatal vasculogenesis 10, 11 . In light of the growing interest in vasculogenesis and anti-angiogenic therapy trials, we encourage the authors to clarify the issue.
